Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

101. Psychosis and schizophrenia

Psychosis and schizophrenia Psychosis and schizophrenia - NICE CKS Share Psychosis and schizophrenia: Summary Psychosis is a disordered mental state characterized principally by positive symptoms such as hallucinations, delusions, and thought disorder. Psychotic symptoms are cardinal features of psychotic disorders such as schizophrenia, but may be caused by medicines and substance misuse, and by medical conditions such as sepsis in the elderly. Psychotic disorders, including schizophrenia (...) symptoms, or Other experiences or behaviour suggestive of possible psychosis (for example, suspicion, mistrust, or perceptual changes), or A first-degree relative with a psychotic disorder including schizophrenia. People at risk of developing a psychotic disorder and people with psychotic symptoms should be assessed to determine their risk of harm to themselves and others. If the person is judged to be at high risk of harm to themselves or others, same-day specialist mental health assessment

2016 NICE Clinical Knowledge Summaries

102. Vitamin D in schizophrenia: a clinical review Full Text available with Trip Pro

Vitamin D in schizophrenia: a clinical review Vitamin D in schizophrenia: a clinical review | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin D in schizophrenia: a clinical review Article Text Clinical review Vitamin D in schizophrenia: a clinical review Mathew Chiang , Radhika Natarajan , Xiaoduo Fan , Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which

2016 Evidence-Based Mental Health

103. Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Full Text available with Trip Pro

Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Article Text Psychological interventions Targeting social and non-social cognition

2016 Evidence-Based Mental Health

104. Alpha-7 nicotinic agonist improves cognition in schizophrenia

Alpha-7 nicotinic agonist improves cognition in schizophrenia Alpha-7 nicotinic agonist improves cognition in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Alpha-7 nicotinic agonist improves cognition in schizophrenia Article Text Pharmacological interventions Alpha-7 nicotinic agonist improves cognition in schizophrenia Stephen R. Marder Statistics from Altmetric.com ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N

2016 Evidence-Based Mental Health

105. Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?

Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Article Text Electronic pages Pharmacological interventions Which

2016 Evidence-Based Mental Health

106. Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis

Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Article Text Pharmacological interventions Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Taro Kishi Statistics from Altmetric.com ABSTRACT FROM: Samara MT, Leucht C, Leeflang MM, et al . Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J

2016 Evidence-Based Mental Health

107. Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Full Text available with Trip Pro

Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Article Text Causes and risk

2016 Evidence-Based Mental Health

108. Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study Full Text available with Trip Pro

Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study Brain-derived neurotrophic factor (BDNF) and nitric oxide (NO) play multiple roles in the developing and adult CNS. Since BDNF and NO metabolisms are dysregulated in schizophrenia, we measured these markers simultaneously in the blood of schizophrenics and assessed their diagnostic accuracy.Thirty-eight patients with schizophrenia classified according to demographic (...) good diagnostic accuracy, but BDNF had better ROC curve characteristics, especially in patients with negative symptomatology.BDNF and nitrite/nitrate showed inverse changes in schizophrenic patients. The most pronounced changes were found in patients treated with second-generation antipsychotics. Although BDNF is not specific of schizophrenia, it may be a clinically useful biomarker for the diagnosis of patients expressing predominantly negative symptoms.

2015 Journal of medical biochemistry

109. [Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. (Abstract)

[Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. The present research paper aims at assessing the effectiveness of a psychoeducational intervention in relatives' groups of patients with schizophrenia or schizoaffective disorder. It examines the possible influence of the intervention on family members as well as on the course of the patient illness. Of a total of 131 relatives, 83 consisted the experimental group and 48 the control group

2015 Psychiatrike = Psychiatriki

110. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

111. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Full Text available with Trip Pro

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013 and August 26, 2015) which is based on regular searches of CINAHL, BIOSIS, AMED

2015 Cochrane

112. Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses | CADTH.ca Find the information you need Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Published on: December 15, 2011 Project Number: HO503 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (...) (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appraise the clinical and cost-effectiveness of combination and high-dose therapy with atypical antipsychotic agents for the treatment of schizophrenia Develop optimal use recommendations or advice Identify gaps in current

2015 CADTH - Optimal Use

113. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Full Text available with Trip Pro

Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural disturbances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some evidence that early intervention services can help, and diagnostic techniques that could contribute to early (...) an individual will progress on to developing schizophrenia as opposed to other types of psychosis.To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants who have received a clinical diagnosis of first episode psychosis.In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP.We included retrospective and prospective studies that consecutively or randomly selected adolescent

2015 Cochrane

114. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

115. Lurasidone (Latuda) - schizophrenia

Lurasidone (Latuda) - schizophrenia Final Appraisal Recommendation Advice No: 0115 – February 2015 Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets Submission by Sunovion Pharmaceuticals Europe Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1142), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant (...) being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0115: Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets. February 2015. Recommendation of AWMSG Lurasidone (Latuda ® ? ) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults aged 18 years and over.

2015 All Wales Medicines Strategy Group

116. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

in schizophrenic mothers confirm previous findings in the context of newer antipsychotic drugs and treatment practices. Women with schizophrenia should be counselled about increased risks and followed by a provider specialising in high-risk pregnancies. Strategies to address modifiable risk factors during pregnancy and the perinatal period are necessary. Special attention should be given to smoking cessation and control of blood pressure. Novel findings include increased rates of thromboembolic disease (...) Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our

2015 Evidence-Based Nursing

117. Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder

Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder REXULTI (brexpiprazole) Tablets U.S. Department of Health and Human Services Search FDA Submit search REXULTI (brexpiprazole) Tablets ENTRESTO Company: Otsuka Pharmaceutical Company, Ltd. Application No.: 205422Orig1s000 and 205422Orig2s000 Approval Date: July 10, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2015 FDA - Drug Approval Package

118. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from

2015 Evidence-Based Mental Health

119. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia

Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Article Text Causes and risk factors Environmental

2015 Evidence-Based Mental Health

120. Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults

Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults Vraylar (Cariprazine) U.S. Department of Health and Human Services Search FDA Submit search Vraylar (Cariprazine) Vraylar (Cariprazine) Company: Forest Laboratories, LLC Application No.: 204370 Orig1 and Orig2 Approval Date: September 17, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package